TY - JOUR

T1 - Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth

AU - Cetin, Irene

AU - Carlson, Susan E

AU - Burden, Christy

AU - da Fonseca, Eduardo B

AU - di Renzo, Gian Carlo

AU - Hadjipanayis, Adamos

AU - Harris, William S

AU - Kumar, Kishore R

AU - Olsen, Sjurdur Frodi

AU - Mader, Silke

AU - McAuliffe, Fionnuala M

AU - Muhlhausler, Beverly

AU - Oken, Emily

AU - Poon, Liona C

AU - Poston, Lucilla

AU - Ramakrishnan, Usha

AU - Roehr, Charles C

AU - Savona-Ventura, Charles

AU - Smuts, Cornelius M

AU - Sotiriadis, Alexandros

AU - Su, Kuan-Pin

AU - Tribe, Rachel M

AU - Vannice, Gretchen

AU - Koletzko, Berthold

AU - Clinical Practice Guideline on behalf of Asia Pacific Health Association (Pediatric-Neonatology Branch), Child Health Foundation (Stiftung Kindergesundheit), European Academy of Paediatrics, European Board & College of Obstetrics and Gynaecology, European

N1 - Copyright © 2023. Published by Elsevier Inc.

PY - 2024

Y1 - 2024

N2 - This clinical practice guideline on the supply of the omega-3 docosahexaenoic acid and eicosapentaenoic acid in pregnant women for risk reduction of preterm birth and early preterm birth was developed with support from several medical-scientific organizations, and is based on a review of the available strong evidence from randomized clinical trials and a formal consensus process. We concluded the following. Women of childbearing age should obtain a supply of at least 250 mg/d of docosahexaenoic+eicosapentaenoic acid from diet or supplements, and in pregnancy an additional intake of ≥100 to 200 mg/d of docosahexaenoic acid. Pregnant women with a low docosahexaenoic acid intake and/or low docosahexaenoic acid blood levels have an increased risk of preterm birth and early preterm birth. Thus, they should receive a supply of approximately 600 to 1000 mg/d of docosahexaenoic+eicosapentaenoic acid, or docosahexaenoic acid alone, given that this dosage showed significant reduction of preterm birth and early preterm birth in randomized controlled trials. This additional supply should preferably begin in the second trimester of pregnancy (not later than approximately 20 weeks' gestation) and continue until approximately 37 weeks' gestation or until childbirth if before 37 weeks' gestation. Identification of women with inadequate omega-3 supply is achievable by a set of standardized questions on intake. Docosahexaenoic acid measurement from blood is another option to identify women with low status, but further standardization of laboratory methods and appropriate cutoff values is needed. Information on how to achieve an appropriate intake of docosahexaenoic acid or docosahexaenoic+eicosapentaenoic acid for women of childbearing age and pregnant women should be provided to women and their partners.

AB - This clinical practice guideline on the supply of the omega-3 docosahexaenoic acid and eicosapentaenoic acid in pregnant women for risk reduction of preterm birth and early preterm birth was developed with support from several medical-scientific organizations, and is based on a review of the available strong evidence from randomized clinical trials and a formal consensus process. We concluded the following. Women of childbearing age should obtain a supply of at least 250 mg/d of docosahexaenoic+eicosapentaenoic acid from diet or supplements, and in pregnancy an additional intake of ≥100 to 200 mg/d of docosahexaenoic acid. Pregnant women with a low docosahexaenoic acid intake and/or low docosahexaenoic acid blood levels have an increased risk of preterm birth and early preterm birth. Thus, they should receive a supply of approximately 600 to 1000 mg/d of docosahexaenoic+eicosapentaenoic acid, or docosahexaenoic acid alone, given that this dosage showed significant reduction of preterm birth and early preterm birth in randomized controlled trials. This additional supply should preferably begin in the second trimester of pregnancy (not later than approximately 20 weeks' gestation) and continue until approximately 37 weeks' gestation or until childbirth if before 37 weeks' gestation. Identification of women with inadequate omega-3 supply is achievable by a set of standardized questions on intake. Docosahexaenoic acid measurement from blood is another option to identify women with low status, but further standardization of laboratory methods and appropriate cutoff values is needed. Information on how to achieve an appropriate intake of docosahexaenoic acid or docosahexaenoic+eicosapentaenoic acid for women of childbearing age and pregnant women should be provided to women and their partners.

KW - Female

KW - Infant, Newborn

KW - Pregnancy

KW - Humans

KW - Fatty Acids, Omega-3/therapeutic use

KW - Docosahexaenoic Acids/therapeutic use

KW - Premature Birth/epidemiology

KW - Eicosapentaenoic Acid

KW - Risk Reduction Behavior

U2 - 10.1016/j.ajogmf.2023.101251

DO - 10.1016/j.ajogmf.2023.101251

M3 - Review

C2 - 38070679

VL - 6

JO - American journal of obstetrics & gynecology MFM

JF - American journal of obstetrics & gynecology MFM

SN - 2589-9333

IS - 2

M1 - 101251

ER -